Background
Methods
Study design
Systematic review
Survey
Outcomes
Statistical analysis
Results
Search results
Characteristics of trials included in the survey
Trial name | Participants | Intervention | Comparator | Outcome | Baseline mortality (%) | Postulated mortality effectb (%) | Power (%) | Sample Size |
---|---|---|---|---|---|---|---|---|
A Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Recombinant Pseudomonas Vaccine in Intensive Care Patients | Adults requiring ICU ventilation for ≥48 h | Recombinant Pseudomonas vaccine | Placebo | Day 28 mortality | 27.5 | 10 | 90 | 800 |
ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients with Septic Shock | Adults who are ventilated with septic shock | Hydrocortisone | Placebo | Day 90 mortality | 33 | 5 | 90 | 3800 |
Early Spontaneous Breathing in ARDS | Adults ventilated with ARDS | APRV | Volume control ventilation | Day 28 mortality | 35 | 10 | 80 | 700 |
Non-sedation versus Sedation with a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation | Adults ventilated in ICU | Nonsedation | Daily awakening | Day 90 mortality | 39 | 10 | 80 | 700 |
Stress Ulcer Prophylaxis in the Intensive Care Unit | Adults with shock, coagulopathy, or receiving RRT or ventilation | Pantoprazole | Placebo | Day 90 mortality | 25 | 5 | 90 | 3350 |
The Augmented versus Routine Approach to Giving Energy Trial | Ventilated adults expected to require enteral nutrition for ≥2 days in ICU | Nutrition at 1.5 kcal/kg/h | Nutrition at 1.0 kcal/kg/h | Day 90 mortality | 25 | 3.95 | 80 | 4000 |
The SuDDICU Cluster RCT of Antibiotic Prophylaxis in Critical Illness | Adults ventilated for ≥24 h in the ICU | SDD | Placebo | In-hospital mortality | 25 | 3.5 | 90 | 24,000 |
Ticagrelor in Severe CAP | Adults with severe CAP requiring ICU admission | Ticagrelor | Placebo | Day 90 mortality | 33 | 11 | 80 | 568 |
Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double-blind placebo-controlled trial | Adults with acute significant GI bleeding | Tranexamic acid | Placebo | Day 28 mortality | 10 | 2.5 | 90 | 8000 |
Tranexamic acid for the treatment of significant traumatic brain injury: an international, randomised, double-blind, placebo-controlled trial | Traumatic brain injury | Tranexamic acid | Placebo | Day 28 mortality | 20 | 3 | 90 | 10,000 |
Survey results
Responses
Demographics
Probabilities, effect size, and sample size
Trial name | Prior probability estimatesa (%) | Chance of a true-positiveb (%) | ||
---|---|---|---|---|
Median estimate (IQR) | Range of estimates | Median calculated chance (IQR) | Range of calculated chances | |
A Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Recombinant Pseudomonas Vaccine in Intensive Care Patients | 5 (0.33–20) | 0–82 | 49 (6–82) | 0–99 |
ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients with Septic Shock | 20 (5–50) | 0–100 | 82 (49–95) | 0–100 |
Early Spontaneous Breathing in ARDS | 10 (1–25) | 0–100 | 64 (14–84) | 0–100 |
Non-sedation versus Sedation with a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation | 20 (5–40) | 0–100 | 80 (46–91) | 0–100 |
Stress Ulcer Prophylaxis in the Intensive Care Unit | 10 (0.030–28.75) | 0–100 | 67 (1–88) | 0–100 |
The Augmented versus Routine Approach to Giving Energy Trial | 10 (2–40) | 0–90 | 64 (29–91) | 0–99 |
The SuDDICU Cluster RCT of Antibiotic Prophylaxis in Critical Illness | 25 (10–50) | 0–100 | 86 (67–95) | 0–100 |
Ticagrelor in Severe CAP | 2.5 (0–10) | 0–100 | 29 (0–64) | 0–100 |
Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double-blind, placebo-controlled trial | 35 (10–57.5) | 0–100 | 91 (67–96) | 0–100 |
Tranexamic acid for the treatment of significant traumatic brain injury: an international, randomised, double-blind, placebo-controlled trial | 20 (10–50) | 0–100 | 82 (67–95) | 0–100 |
Trial name | Effect size (%) | Sample size | ||
---|---|---|---|---|
Median largest absolute mortality reduction considered plausible (IQR, range) | Absolute mortality reduction postulated by trialists | Size required to detect median largest effect size considered plausible | Actual | |
A Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Recombinant Pseudomonas Vaccine in Intensive Care Patients | 5 (2–6, 0–23)) | 10 | 3186 | 800 |
ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients with Septic Shock | 5 (3–10, 0–33) | 5 | 3556 | 3800 |
Early Spontaneous Breathing in ARDS | 5 (2–10, 0–35) | 10 | 2748 | 700 |
Non-sedation versus Sedation with a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation | 5 (3–15, 0–39) | 10 | 2904 | 700 |
Stress Ulcer Prophylaxis in the Intensive Care Unit | 3 (1–5, 0–25) | 5 | 8388 | 3350 |
The Augmented versus Routine Approach to Giving Energy Trial | 3 (1–5, 0–25) | 3.95 | 6266 | 4000 |
The SuDDICU Cluster RCT of Antibiotic Prophylaxis in Critical Illness | 5 (3–9, 0–24) | 3.5 | Not calculateda
| 24,000 |
Ticagrelor in Severe CAP | 3 (1–5, 0–33) | 11 | 7522 | 568 |
Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double-blind, placebo-controlled trial | 3 (2–5, 0–10) | 2.5 | 3624 | 8000 |
Tranexamic acid for the treatment of significant traumatic brain injury: an international, randomised, double-blind, placebo-controlled trial | 4 (2–5, 0–10) | 3 | 3868 | 10,000 |